These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11750347)

  • 41. Comparison of C0 and C2 cyclosporine monitoring in long-term renal transplant recipients.
    Marcén R; Pascual J; Tato A; Villafruela JJ; Teruel JL; Rivera ME; Tenorio M; Fernández M; Burgos FJ; Ortuño J
    Transplant Proc; 2003 Aug; 35(5):1780-2. PubMed ID: 12962793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
    Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
    Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive value of cyclosporine blood levels during the absorption phase to estimate the area under the curve in stable renal transplant patients.
    Sabaté I; Calzada P; Gil-Vernet S; Fulladosa X; Baró S; González C; Castro MJ; Castelao AM; Grinyó JM
    Transplant Proc; 2002 Feb; 34(1):140-1. PubMed ID: 11959224
    [No Abstract]   [Full Text] [Related]  

  • 44. Therapeutic drug monitoring of cyclosporine.
    Midtvedt K
    Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validation of sparse sampling strategies to estimate cyclosporine A area under the concentration-time curve using either a specific radioimmunoassay or high-performance liquid chromatography method.
    Koristkova B; Grundmann M; Brozmanova H; Perinova I; Safarcik K
    Ther Drug Monit; 2010 Oct; 32(5):586-93. PubMed ID: 20683391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between maintenance dose of cyclosporine and long-term kidney graft survival. Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1998 Aug; 30(5):1716-7. PubMed ID: 9723253
    [No Abstract]   [Full Text] [Related]  

  • 47. Conventional versus Neoral cyclosporine in renal transplantation.
    Rovelli E; Bucci A; Maldifassi P; Belfiore A; D'Amico G
    Transplant Proc; 1998 Aug; 30(5):1764-5. PubMed ID: 9723272
    [No Abstract]   [Full Text] [Related]  

  • 48. Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy.
    Barbari A; Stephan A; Masri M; Mourad N; Kamel G; Kilani H; Karam A; Daya IA
    Transplant Proc; 2003 Nov; 35(7):2742-4. PubMed ID: 14612101
    [No Abstract]   [Full Text] [Related]  

  • 49. Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling?
    Gaspari F; Caruso R; Cattaneo D; Perico N; Remuzzi G
    Transplant Proc; 2001; 33(7-8):3117-9. PubMed ID: 11750340
    [No Abstract]   [Full Text] [Related]  

  • 50. Optimization of cyclosporine exposure utilizing C(2) level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience.
    Maham N; Cardella C; Cattran D; Fenton S; O'Grady C; Hamill J; Smith R; Cole E
    Transplant Proc; 2001; 33(7-8):3098-9. PubMed ID: 11750331
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of different sampling times for best prediction of cyclosporine area under the curve in renal transplant recipients.
    Sud K; Singh B; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Transplant Proc; 2002 Dec; 34(8):3168-70. PubMed ID: 12493408
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical benefit of monitoring cyclosporine C2 and C4 in long-term liver transplant recipients.
    Barakat O; Peaston R; Rai R; Talbot D; Manas D
    Transplant Proc; 2002 Aug; 34(5):1535-7. PubMed ID: 12176472
    [No Abstract]   [Full Text] [Related]  

  • 54. Cyclosporine blood concentration at 2 hours (C(2)) from drug ingestion as the best single indicator of adequate cyclosporine immunosuppression in renal allograft recipients--a four-year follow-up.
    Baczkowska T; Serafinowicz A; Kukuła K; Nowacka-Cieciura E; Cieciura T; Deborska D; Gałazka Z; Rowiński W; Szmidt J; Durlik M; Lao M
    Transplant Proc; 2002 Mar; 34(2):556-7. PubMed ID: 12009622
    [No Abstract]   [Full Text] [Related]  

  • 55. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation.
    Hami M; Naghibi M; Mojahedi MJ; Sharifipour F; Shakeri MT
    Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1169-74. PubMed ID: 23168844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 3-hour postdose cyclosporine level during the first week after kidney transplantation predicts acute rejection and cyclosporine nephrotoxicity more accurately than trough levels.
    Mahalati K; Belitsky P; West K; Kiberd B; MacDonald A; McAlister V; Lawen J
    Transplant Proc; 2000 Jun; 32(4):786-7. PubMed ID: 10856585
    [No Abstract]   [Full Text] [Related]  

  • 57. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients.
    Balram C; Sivathasan C; Cheung YB; Tan SB; Tan YS
    J Heart Lung Transplant; 2002 Sep; 21(9):1016-21. PubMed ID: 12231373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
    Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
    Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: is there any threat for chronic rejection development?
    Ferraresso M; Ghio L; Edefonti A; Vigano S; Boschiero L; Berardinelli L
    Pediatr Transplant; 2005 Jun; 9(3):328-31. PubMed ID: 15910389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.